Evidence map›Paper›PMID 26519084›Full record

ArticleBMC cancer2015

Leukocyte telomere length and its association with mammographic density and proliferative diagnosis among women undergoing diagnostic image-guided breast biopsy.

Clara Bodelon, Christopher M Heaphy, Alan K Meeker, Berta Geller, Pamela M Vacek, Donald L Weaver, Rachael E Chicoine, John A Shepherd, Amir Pasha Mahmoudzadeh, Deesha A Patel and 3 more

Abstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Cocaine use may induce telomere shortening in individuals with HIV infection.Progress in neuro-psychopharmacology & biological psychiatry · 2018
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Clara BodelonHormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA. clara.bodelon@nih.gov.
Christopher M HeaphyDepartment of Pathology, John Hopkins University School of Medicine, Baltimore, MD, USA. cheaphy@jhmi.edu.
Alan K MeekerDepartments of Pathology, Oncology and Urology, John Hopkins University School of Medicine, Baltimore, MD, USA. alan.meeker@gmail.com.
Berta GellerDepartment of Health Promotion Research, University of Vermont College of Medicine and Vermont Cancer Center, Burlington, VT, USA. berta.geller@uvm.edu.
Pamela M VacekDepartment of Biostatistics, University of Vermont College of Medicine and Vermont Cancer Center, Burlington, VT, USA.
Donald L WeaverDepartment of Pathology, University of Vermont College of Medicine and Vermont Cancer Center, Burlington, VT, USA. donald.weaver@uvm.edu.
Rachael E ChicoineOffice of Health Promotion Research, University of Vermont College of Medicine and Vermont Cancer Center, Burlington, VT, USA. rchicoin@uvm.edu.
John A ShepherdDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA. John.Shepherd@ucsf.edu.
Amir Pasha MahmoudzadehDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA. pmahmoudzadeh@gmail.com.
Deesha A PatelHormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA. deesha.patel@nih.gov.
Louise A BrintonHormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA. brintonl@exchange.nih.gov.
Mark E ShermanBreast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA. shermanm@exchange.nih.gov.
Gretchen L GierachHormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA. gierachg@mail.nih.gov.

Funding

Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
WEIGHT MAINTENANCE AND PSYCHOLOGICAL BENEFITS OF EXERCISEM01RR000109 · NCRR · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI DUMAS, JULIE A · 1985 to 2010
$24.3M
VERMONT BREAST CANCER SURVEILLANCE SYSTEMU01CA070013 · NCI · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI GELLER, BERTA M · 1995 to 2011
$6.7M
Lesion Composition and Quantitative Imaging Analysis on Breast Cancer DiagnosisR01CA166945 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GIGER, MARYELLEN L., SHEPHERD, JOHN ALAN · 2013 to 2017
$3.3M
Subregional Breast Density and Cancer RiskR21CA157254 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHEPHERD, JOHN ALAN · 2012 to 2013
$357k
CCR NIH HHS HHSN261200800001CIntramural NIH HHSNCI NIH HHS 1R21CA157254NCI NIH HHS HHSN261200800001ENCI NIH HHS R01 CA166945NCI NIH HHS R21 CA157254NCI NIH HHS U01 CA070013NCI NIH HHS U01CA70013NCRR NIH HHS M01 RR000109
6 · The paper itself

Abstract

backgroundElevated mammographic density (MD) is a strong breast cancer risk factor but the mechanisms underlying the association are poorly understood. High MD and breast cancer risk may reflect cumulative exposures to factors that promote epithelial cell division. One marker of cellular replicative history is telomere length, but its association with MD is unknown. We investigated the relation of telomere length, a marker of cellular replicative history, with MD and biopsy diagnosis.

methodsOne hundred and ninety-five women, ages 40-65, were clinically referred for image-guided breast biopsies at an academic facility in Vermont. Relative peripheral blood leukocyte telomere length (LTL) was measured using quantitative polymerase chain reaction. MD volume was quantified in cranio-caudal views of the breast contralateral to the primary diagnosis in digital mammograms using a breast density phantom, while MD area (cm(2)) was measured using thresholding software. Associations between log-transformed LTL and continuous MD measurements (volume and area) were evaluated using linear regression models adjusted for age and body mass index. Analyses were stratified by biopsy diagnosis: proliferative (hyperplasia, in-situ or invasive carcinoma) or non-proliferative (benign or other non-proliferative benign diagnoses).

resultsMean relative LTL in women with proliferative disease (n = 141) was 1.6 (SD = 0.9) vs. 1.2 (SD = 0.6) in those with non-proliferative diagnoses (n = 54) (P = 0.002). Mean percent MD volume did not differ by diagnosis (P = 0.69). LTL was not associated with MD in women with proliferative (P = 0.89) or non-proliferative (P = 0.48) diagnoses. However, LTL was associated with a significant increased risk of proliferative diagnosis (adjusted OR = 2.46, 95% CI: 1.47, 4.42).

conclusionsOur analysis of LTL did not find an association with MD. However, our findings suggest that LTL may be a marker of risk for proliferative pathology among women referred for biopsy based on breast imaging.

Indexed as

AdultAgedBreast DensityBreast NeoplasmsCross-Sectional StudiesFemaleHumansImage-Guided BiopsyLeukocytesMammary Glands, HumanMiddle AgedNeoplasm StagingRisk FactorsTelomere

Identifiers

PMID26519084
PMCPMC4628256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.